Wire · operational-macro
Neovii Advances FDA Fast Track-Designated ATLG Program in Type 1 Diabetes with Pivotal ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 October 2026 · Fusion42 review
Neovii Pharmaceuticals is advancing its FDA Fast Track-designated anti-T-lymphocyte globulin (ATLG) program for Type 1 Diabetes with a pivotal Phase 2 study across the US and EU, building on ongoing European clinical data. The company has appointed Dr. Salvatore Alesci as Chief Medical Officer to lead clinical development and regulatory strategy as Neovii expands into immune-mediated diseases.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have a clearer path to US and EU markets for ATLG in Type 1 Diabetes as Neovii's pivotal study advances with FDA Fast Track support. Drug developers in immune modulation can reposition their pipelines around this validation and regulatory momentum.
◆ Coverage
1 source · 22 Oct 2026
◆ Related on Wire
◆ Topics